Helps increase Time in Range with less effort.1
Anticipates
Monitors and anticipates insulin needs based on real-time glucose data and personal trends.
Adjusts
Makes precise adjustments of rapid-acting insulin to help smooth out highs and lows.
Corrects
Automatically corrects highs for under-estimated carb counts and an occasionally missed meal dose.4
SMARTGUARD™ TECHNOLOGY
Advanced SmartGuard™ tech helps increase Time in Range with less effort3
The MiniMed™ 780G system with advanced SmartGuard™ tech provides you a more effortless way to stabilise your glucose levels. With new auto correction dosing, the system continuously checks your glucose levels and automatically adjusts insulin delivery and corrects highs to help keep you in range*.
On average, users spend
76% of their Time in Range3.
Easy-to-use smartphone apps help you stay in the know.
MiniMed™ mobile app for people living with diabetes
You can now view your diabetes data on your smartphone, allowing you to easily track your glucose levels and get notified on your phone if you’re trending high or low.
Available to download at no cost for most iOS and Android smartphones.5
CareLink™ connect app for care partners
This app helps keep care partners in the loop. Securely invite up to 5 people to view insulin pump and sensor data, receive high and low notifications, and more.
Available to download at no cost for most iOS and Android smartphones.5
NDSS Subsidy for people living with type 1 diabetes
Access subsidised Guardian™ 4 Sensor via the NDSS
Medtronic welcomes the commitment made by the Coalition and Labor to enable expanded access to publicly funded Continuous Glucose Monitoring (CGM) for all patients with Type 1 Diabetes in Australia.
Real people. Real experiences.
Our advanced technology to navigate your own unique diabetes journey.
The system is for type 1 ages 7 and over. Prescription required. WARNING: Do not use SmartGuard™ feature for people who require less than 8 units or more than 250 units of insulin/day. See bit.ly/780gRisks.
The system is for type 1 ages 7 and over. Prescription required. WARNING: Do not use SmartGuard™ feature for people who require less than 8 units or more than 250 units of insulin/day. See bit.ly/780gRisks
MiniMed™ 780G system
Insulin pump
Based on info received from the CGM every 5 minutes, the pump makes automatic adjustments and corrections to your insulin delivery.
Continuous Glucose Monitor (CGM)
The calibrations free* 1, 2 Guardian™ 4 sensor measures glucose levels every 5 minutes, sending levels to the pump.
Infusion set
Allows for continuous and discreet delivery of insulin through a thin, flexible tube and can be worn up to 7 days.
Smartphone app
Get notified of highs and lows with the MiniMed™ Mobile app. Care partners can download the CareLink™ Connect app to stay in the know.
Apple® smart watchΦ
Get alerts for highs or lows directly to your Apple® smart watch with the MiniMed™ Mobile app.
Φ Smart devices sold separately. Find a list of compatible devices. * if sensor glucose (SG) values do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. Refer to System User Guide.
What’s new with MiniMed™ 780G system^?
|
MiniMed™ 780G system^
 |
MiniMed™ 770G system^
 |
||
|
Automatically** corrects highs to help make up for inexact carb counts or an occasionally missed meal dose. |
 |
 |
|
|
No calibrations.* |
|
|
|
|
Personalised glucose targets. |
|
|
|
|
Automatically** adjusts insulin delivery |
|
|
|
|
Track your glucose levels on your smartphone. |
|
|
|
|
Friends and family can view your glucose trends on their smartphone. |
|
|
Frequently asked questions
The MiniMed™ 780G system^ is approved for people with type 1 diabetes age 7 and above whose daily dose of insulin is 8 units per day or more. To learn more about insulin pump therapy for children please click here. If you would prefer not to wear a CGM, the MiniMed™ 640G system may be a better fit for you. If you would like a CGM and not an insulin pump, consider looking into the Guardian™ Connect CGM.
Yes. The MiniMed™ 780G system^ transmits to your smartphone via wireless technology. You and your care partners are able to see real-time blood glucose trends on a smartphone anytime. Available to download at no cost for most iOS and Android smartphones.
To see if your smartphone is compatible, see this reference chart.
Discover the ease of automated insulin delivery.
Request a call today to discuss the benefits of insulin pump therapy with a Medtronic Diabetes Therapy Consultant.
This form takes less than ~60 seconds to complete.
ALWAYS FOLLOW THE DIRECTIONS FOR USE.
The MiniMed 780G insulin pump is indicated for use by patients age 7-80 years with Type 1 diabetes, whose total daily dose of insulin is 8 units per day or more. The MiniMed 780G system is intended for the continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts. The system is also intended to continuously monitor glucose values in the fluid under the skin. The MiniMed 780G system includes SmartGuard technology, which can be programmed to provide an automatic adjustment of insulin delivery based on continuous glucose monitoring (CGM) and can suspend the delivery of insulin when the SG value falls below, or is predicted to fall below, predefined threshold values.
Automated insulin delivery is made possible through combining Medtronic insulin pump and continuous glucose monitoring technology. Some user interaction required. Individual responses to the treatment can and do vary Consult a healthcare professional to see if this product is suitable for you.
The Guardian 4 sensor is intended for use with the Guardian 4 transmitter to monitor glucose levels in persons with diabetes where self-monitoring of blood glucose (SMBG) is indicated. The sensor is designed to replace fingerstick blood glucose (BG)readings for diabetes treatment decisions. The sensor is intended for insertion into persons ages 7 years and older. The sensor is intended for insertion into the back of the upper arm or the upper buttocks in persons ages 7 through 17 years. The sensor is intended for insertion into the back of the upper arm or the abdomen in persons ages 18 years and older.
References
^ Components sold separately.
1. Carlson, A.L. et al. Safety and Glycemic Outcomes During the MiniMed Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes. DIABETES TECHNOLOGY & THERAPEUTICS. Vol 24, No. 3 (2022) 1-12.
2. Da Silva J, et al. Real-world Performance of the MiniMed™ 780G System: First Report of Outcomes from 4'120 Users. Diabetes Technol Ther. 2021; doi: 10.1089/dia.2021.0203
3. Data on file from CIP 321: Pivotal Trial (Age 7-75). N=283. 2020; 16 US sites.
4. Sherr J.L, et al. Poster A66 Journal of Diabetes Science and Technology 2021; 15(2) 397–477
5. Google Play and the Google Play logo are trademarks of Google LLC.
§ Compared to the MiniMedTM 770G system. Refers to SmartGuardTM feature. Some user interaction required.
* if sensor glucose (SG) values do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. Refer to System User Guide.
** Refers to SmartGuard™ feature. Individual results may vary.
† At the time of manufacture and when the reservoir and tubing are properly inserted, your pump is waterproof. It is protected against the effects of being underwater to a depth of up to 12 feet (3.6 meters) for up to 24 hours. This is classified as IPX8 rating. See user guide for more details. The sensor and transmitter are water-resistant at 8 feet (2.4 meters) for up to 30 minutes. CGM readings may not be transmitted from the CGM to the pump while in water.
‡ Assumes 4 injections per day for 30 days and one infusion set change every seven days for extended infusion set.